Elena Myasoedova1, Cynthia S Crowson2,3, Rachel E Giblon3, Kathleen McCarthy-Fruin2, Daniel E Schaffer2, Kerry Wright2, Eric L Matteson2, John M Davis2. 1. Division of Rheumatology, Department of Internal Medicine, Mayo Clinic College of Medicine and Science, 200 1st St. SW, Rochester, MN, 55905, USA. myasoedova.elena@mayo.edu. 2. Division of Rheumatology, Department of Internal Medicine, Mayo Clinic College of Medicine and Science, 200 1st St. SW, Rochester, MN, 55905, USA. 3. Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Abstract
INTRODUCTION/ OBJECTIVES: To evaluate the effect of a flare management intervention guided by non-physician providers versus usual care between rheumatology visits on flare occurrence and rheumatoid arthritis (RA) disease activity. METHODS:Adult patients with established RA (per 2010 ACR criteria, n = 150) were randomized to the intervention arm (n = 75) versus usual care (n = 75). The Flare Assessment in Rheumatoid Arthritis (FLARE-RA) questionnaire was administered monthly during 24 months to all patients in the intervention arm to assess flare status. Telephone nurse-led counseling or an expedited visit with a rheumatology provider was offered to patients in the intervention arm who indicated they were in flare. RESULTS: Patients in the intervention arm completed a median of 8.5 (range 1-24) questionnaires. RA flare was reported on 122 (19%) of these questionnaires; average FLARE-RA score, 4.72 on 0 (no flare) to 10 (maximum flare) scale. Patients preferred an expedited clinic visit with a rheumatology provider during 39 (32%) of flares. The majority of patients preferred to self-manage their flare (76, 62%); some patients received nursing advice on flare management over the phone (7, 6%). There were no differences in RA flare by OMERACT9 definition, DAS28-CRP, CDAI, SDAI, anti-rheumatic treatment change by rheumatology provider, or remission by CDAI between the study arms over 24-month follow-up. CONCLUSIONS: The flare management intervention did not have any major effect on flare occurrence or RA disease activity metrics over the 24-month follow-up. The majority of patients in the intervention arm preferred self-management to an expedited visit with their rheumatology provider. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02382783 ( https://clinicaltrials.gov/ct2/show/NCT02382783 ) Key Points • The flare management intervention had no effect on rheumatoid arthritis (RA) disease activity. • Patients preferred self-management of their RA flares to expedited rheumatology provider visits.
RCT Entities:
INTRODUCTION/ OBJECTIVES: To evaluate the effect of a flare management intervention guided by non-physician providers versus usual care between rheumatology visits on flare occurrence and rheumatoid arthritis (RA) disease activity. METHODS: Adult patients with established RA (per 2010 ACR criteria, n = 150) were randomized to the intervention arm (n = 75) versus usual care (n = 75). The Flare Assessment in Rheumatoid Arthritis (FLARE-RA) questionnaire was administered monthly during 24 months to all patients in the intervention arm to assess flare status. Telephone nurse-led counseling or an expedited visit with a rheumatology provider was offered to patients in the intervention arm who indicated they were in flare. RESULTS:Patients in the intervention arm completed a median of 8.5 (range 1-24) questionnaires. RA flare was reported on 122 (19%) of these questionnaires; average FLARE-RA score, 4.72 on 0 (no flare) to 10 (maximum flare) scale. Patients preferred an expedited clinic visit with a rheumatology provider during 39 (32%) of flares. The majority of patients preferred to self-manage their flare (76, 62%); some patients received nursing advice on flare management over the phone (7, 6%). There were no differences in RA flare by OMERACT9 definition, DAS28-CRP, CDAI, SDAI, anti-rheumatic treatment change by rheumatology provider, or remission by CDAI between the study arms over 24-month follow-up. CONCLUSIONS: The flare management intervention did not have any major effect on flare occurrence or RA disease activity metrics over the 24-month follow-up. The majority of patients in the intervention arm preferred self-management to an expedited visit with their rheumatology provider. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02382783 ( https://clinicaltrials.gov/ct2/show/NCT02382783 ) Key Points • The flare management intervention had no effect on rheumatoid arthritis (RA) disease activity. • Patients preferred self-management of their RA flares to expedited rheumatology provider visits.
Authors: Paco M J Welsing; Robert B M Landewé; Piet L C M van Riel; Maarten Boers; Anke M van Gestel; Sjef van der Linden; Hilde L Swinkels; Désirée M F M van der Heijde Journal: Arthritis Rheum Date: 2004-07
Authors: Clifton O Bingham; Christoph Pohl; Thasia G Woodworth; Sarah E Hewlett; James E May; Mahboob U Rahman; James P Witter; Daniel E Furst; C Vibeke Strand; Maarten Boers; Rieke E Alten Journal: J Rheumatol Date: 2009-08-14 Impact factor: 4.666
Authors: Tina M Backhaus; Sarah Ohrndorf; Herbert Kellner; Johannes Strunk; Wolfgang Hartung; Horst Sattler; Christof Iking-Konert; Gerd R Burmester; Wolfgang A Schmidt; Marina Backhaus Journal: Ann Rheum Dis Date: 2012-09-06 Impact factor: 19.103
Authors: Iris M Markusse; Linda Dirven; Andreas H Gerards; Johannes H L M van Groenendael; H Karel Ronday; Pit J S M Kerstens; Willem F Lems; Tom W J Huizinga; Cornelia F Allaart Journal: Arthritis Res Ther Date: 2015-08-31 Impact factor: 5.156
Authors: Mwidimi Ndosi; Martyn Lewis; Claire Hale; Helen Quinn; Sarah Ryan; Paul Emery; Howard Bird; Jackie Hill Journal: Ann Rheum Dis Date: 2013-08-27 Impact factor: 19.103
Authors: Chris Gibbons; Ian Porter; Daniela C Gonçalves-Bradley; Stanimir Stoilov; Ignacio Ricci-Cabello; Elena Tsangaris; Jaheeda Gangannagaripalli; Antoinette Davey; Elizabeth J Gibbons; Anna Kotzeva; Jonathan Evans; Philip J van der Wees; Evangelos Kontopantelis; Joanne Greenhalgh; Peter Bower; Jordi Alonso; Jose M Valderas Journal: Cochrane Database Syst Rev Date: 2021-10-12
Authors: N Barroso; T G Woodworth; D E Furst; F Guillemin; B J Fautrel; N Borazan; S Kafaja; J Brook; D A Elashoff; V K Ranganath Journal: Clin Rheumatol Date: 2019-09-06 Impact factor: 2.980
Authors: Wieland D Müskens; Sanne A A Rongen-van Dartel; Carine Vogel; Anita Huis; Eddy M M Adang; Piet L C M van Riel Journal: Rheumatol Adv Pract Date: 2021-01-07